vimarsana.com

Latest Breaking News On - Sahar abubucker - Page 1 : vimarsana.com

Epigenetic Editing for Multiplex Gene Regulation Reinforced by Data

Chroma believes the data presented at ASGCT represents an important step toward rapidly advancing novel medicines to patients.

Vic myerLos angelesSahar abubuckerCatherine stehman breenAmerican society of gene cell therapyChroma medicineAmerican societyCell therapyAnnual meeting

Epigenetic Editing for Multiplex Gene Regulation Reinforced by Data

Chroma believes the data presented at ASGCT represents an important step toward rapidly advancing novel medicines to patients.

Vic myerLos angelesSahar abubuckerCatherine stehman breenAmerican society of gene cell therapyChroma medicineAmerican societyCell therapyAnnual meeting

Chroma Medicine Announces Data Demonstrating the Benefits of Epigenetic Editing for Multiplex Gene Regulation at ASGCT 2023

/PRNewswire/ Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented data.

United statesVic myerLos angelesCatherine stehman breenSahar abubuckerChroma medicine incAmerican society of gene cell therapyAmerican societyCell therapyAnnual meetingSenior directorEpigenome editingChroma medicineHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveries

Chroma Medicine Presents Data Demonstrating Near-Complete, Durable In Vivo Silencing with Targeted Epigenetic Editors at 2023 ASGCT Annual Meeting

/PRNewswire/ Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced in vivo data.

United statesAaron jaffeSahar abubuckerVic myerAngelo lombardoChroma medicine incHead of researchAmerican society of gene cell therapyAmerican societyCell therapyAnnual meetingTargeted epigenetic editorNear complete in vivo silencingSenior vice presidentGene targetingGene correction

Chroma Medicine to Present First Data Demonstrating Promise of Its Epigenetic Editing Platform at 26th ASGCT Annual Meeting

/PRNewswire/ Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced two oral.

United statesAaron jaffeLos angelesSahar abubuckerVic myerHead of researchChroma medicine incAmerican society of gene cell therapyAmerican societyCell therapyAnnual meetingTargeted epigenetic editorNear complete in vivo silencingSenior vice presidentGene targetingGene correction

vimarsana © 2020. All Rights Reserved.